01:15:13 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-05 Bokslutskommuniké 2024
2024-10-23 Kvartalsrapport 2024-Q3
2024-07-18 Kvartalsrapport 2024-Q2
2024-05-06 Ordinarie utdelning TDVOX 0.00 SEK
2024-05-03 Årsstämma 2024
2024-04-23 Kvartalsrapport 2024-Q1
2024-02-08 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-07-20 Kvartalsrapport 2023-Q2
2023-05-11 Ordinarie utdelning TDVOX 0.00 SEK
2023-05-10 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-02-08 Bokslutskommuniké 2022
2022-10-28 Kvartalsrapport 2022-Q3
2022-07-21 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning TDVOX 0.00 SEK
2022-05-19 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-08 Bokslutskommuniké 2021

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorInformationsteknik
IndustriElektronisk utrustning
Tobii Dynavox utvecklar och säljer kommunikationshjälpmedel. Bolagets teknik erbjuder en uppsättning av olika lösningar och tjänster som bland annat innefattar specialutvecklade kommunikationsenheter, som styrs med ögonstyrning eller pekskärm, samt ett flertal olika mjukvaror för kommunikation och specialundervisning. Lösningarna används främst av personer med funktionsnedsättningar men även av terapeuter, logopeder, vårdgivare och sjukhus. Bolaget har sitt huvudkontor i Danderyd.
2023-10-27 07:30:00

Tobii Dynavox AB (publ) today announced its results for the third quarter of 2023.

Comment by Tobii Dynavox CEO Fredrik Ruben:

We continue to experience strong growth, despite significantly tougher comparative figures, with all product and user groups on the rise. At the same time, we are making good progress toward our long-term EBIT margin target. In September, we completed the acquisition of the German company Rehadapt, as planned. We continue to invest in skills, systems and tools to ensure continued growth and profitability, while increasing the scalability of the business.

QUARTER JULY - SEPTEMBER 2023
  • Revenue grew 33% to SEK 424 million (320). The currency adjusted growth was 28%. 
  • Gross margin was 68% (67). 
  • Operating profit totaled SEK 48 million (25), corresponding to an operating margin of 11.4% (7.8). The operating margin was 11.6%, excluding non-recurring costs of SEK 1 million.
  • Cash flow after continuous investments was SEK 35 million (-9).
  • Basic and diluted earnings per share were SEK 0.33 (0.15). 
PERIOD JANUARY-SEPTEMBER 2023
  • Revenue grew 33% to SEK 1,141 million (855). The currency adjusted growth was 26%. 
  • Gross margin was 68% (65). 
  • Operating profit totaled SEK 99 million (58), corresponding to an operating margin of 8.6% (6.7). The operating margin was 9.3%, excluding non-recurring costs of SEK 7 million.
  • Cash flow after continuous investments was SEK 82 million (-67).
  • Basic earnings per share totaled SEK 0.56 (0.30) before dilution and SEK 0.55 (0.30) after dilution.
SIGNIFICANT EVENTS DURING THE QUARTER

COMMENTS FROM THE CEO

We continue to experience strong growth, despite significantly tougher comparative figures, with all product and user groups on the rise. At the same time, we are making good progress toward our long-term EBIT margin target. In September, we completed the acquisition of the German company Rehadapt, as planned. We continue to invest in skills, systems and tools to ensure continued growth and profitability, while increasing the scalability of the business.

Sales growth continues to be well above our long-term target at 28% for the quarter, denominated in local currency. In the US, Medicare increased its reimbursement level for our products by more than 9 percent, which will gradually affect revenue in 2023. Approximately 7 percentage points of these price adjustments have materialized thus far and as previously stated, we expect to see the full impact by the end of the year. We continue to see a trend where growth is fastest in markets that have direct sales.

The acquisition of Rehadapt, our longstanding German supplier partner, closed on September 1. Rehadapt provides a natural complement to our offering on mounting solutions for communication aids, while also strengthening our position in Germany. About 30% of Rehadapt's sales relate to sales to Tobii Dynavox. Through this deal, we are pleased to welcome about 50 new team members, mainly in Germany. 

Our growth is affected by an array of factors. While we have a strong product offering and a well-functioning organization, our market remains extremely underpenetrated. In practice, the latter means that the vast majority of people in need of communication aids are never informed about or introduced to the assistive devices we and our industry peers offer. This situation includes the most advanced and wealthy economies. The root cause is a significant knowledge deficit about communication aids among the key groups responsible for prescribing them: speech language therapists and occupational therapists. A contributing factor is that relevant education related to assistive communication aids is either non-existent or severely limited.

Some diagnoses where our products can make a huge difference have received considerable attention recently, including the neurological disease ALS. However, for some of our largest user groups, such as non-verbal autism, aphasia, cerebral palsy and hundreds of other diagnoses, awareness of our solutions among prescribers and options for funding is extremely low. Even in the most well-functioning markets, only a very small number of individuals receive any kind of assistance. Vast opportunities are lost for users, families and society at large, and we are passionately dedicated to changing this situation.

I am confident that our unprecedented growth is a consequence of our relentless efforts to educate and spread awareness combined with products and services that truly make a difference - and, we have barely started. 

Given the situation and our market position, this translates to significant long-term business opportunities for Tobii Dynavox and other players dedicated to helping individuals who cannot adequately communicate with their environment. In short, much remains to be done. We therefore welcome all efforts made by commercial stakeholders, patient organizations and professionals to jointly build this market. If we succeed, the outcome will be an improved life for users, their families, and society at large, along with substantial business opportunities for those who do it right.

Fredrik Ruben, CEO

Webcast
Today at 09:00 a.m. CET, Tobii Dynavox will host a webcast presentation for investors, analysts and press. If you want to attend the webcast click the following link (https://teams.microsoft.com/l/meetup-join/19%3ameeting_YjJkYzk5MmQtMzMyOS00YjBjLWFiOGUtZjBjOTkyMzBlMDY1%40thread.v2/0?context=%7B%22Tid%22%3A%22f253f952-50bd-4884-bd3b-56ba582a9e42%22%2C%22Oid%22%3A%2237130e24-ee78-420d-b628-a05f17aad74b%22%2C%22IsBroadcastMeeting%22%3Atrue%2C%22role%22%3A%22a%22%7D&btype=a&role=a). The interim report and a recording of the webcast will be available here (https://investors.tobiidynavox.com/pages/financial-presentations).

This information is inside information that Tobii Dynavox AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication, through the agency of the contact person set out below, at 07.30 CET on October 27th, 2023.